In Brief: Cordis stent suit
This article was originally published in The Gray Sheet
Cordis stent suit: Johnson & Johnson subsidiary adds Arterial Vascular Engineering, Boston Scientific and SciMed Lifesystems to the list of defendants in its Oct. 3 coronary stent patent infringement suit against Guidant, AVE states. The suit was filed in federal district court in Delaware ("The Gray Sheet" Oct. 13, In Brief). AVE filed a premarket approval application for its coronary stent systems Aug. 4 ("The Gray Sheet" Aug. 18, In Brief). "We have reviewed the lawsuit and believe we have meritorious defenses to the claims alleged and we do not believe this will impact our ability to successfully commercialize our stent systems in the U.S.," AVE states...
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.